| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
As a chemical linker, Amino-Tri-(t-butoxycarbonylethoxymethyl)-methane itself does not have a biological target. Its utility lies in its ability to serve as a trifunctional branching point for the synthesis of multivalent molecules. The three Boc-protected amines allow for the attachment of three different ligands or functional groups after deprotection, while the free amino group provides an additional handle for conjugation. This enables the construction of complex, multifunctional molecules for various research applications.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1]. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system [1].
As a chemical linker, this compound does not exhibit intrinsic biological activity. Its in vitro utility is demonstrated in the synthesis of dendrimers, multivalent ligands, and other branched molecules. The compound's ability to introduce multiple functional groups onto a single scaffold makes it valuable for studying multivalent interactions in biological systems. The synthesized multivalent molecules can be evaluated for their enhanced binding affinity and biological activity. |
| ln Vivo |
As a chemical linker, this compound does not possess intrinsic biological activity and is not evaluated in conventional in vivo efficacy models. Its in vivo relevance is demonstrated through the biological activity of the multivalent molecules it helps to construct. These molecules can be used for targeted drug delivery, imaging, and other biomedical applications where multivalency enhances efficacy.
|
| Enzyme Assay |
In a typical conjugation experiment, Amino-Tri-(t-butoxycarbonylethoxymethyl)-methane is dissolved in an appropriate solvent. The Boc-protected amines can be deprotected using trifluoroacetic acid (TFA) to reveal primary amines, which can then be reacted with carboxylic acids or activated esters. The free amino group can be selectively reacted with a different functional group, enabling orthogonal conjugation. The reactions are typically carried out at room temperature. The products are purified and characterized by NMR and mass spectrometry.
|
| Cell Assay |
Since this compound is a chemical linker, standard in vitro cell-based assays are not directly applicable. However, the multivalent molecules synthesized using this linker can be evaluated for their biological activity in cell-based assays. For example, multivalent ligands targeting cell surface receptors can be assessed for their ability to bind to cells and modulate signaling pathways.
|
| Animal Protocol |
As a chemical linker, this compound is not administered to animals as a therapeutic agent. In vivo studies are conducted with the final multivalent conjugates that incorporate this linker. These studies may involve evaluating the biodistribution, targeting efficiency, and therapeutic efficacy of the multivalent molecules in animal models.
|
| ADME/Pharmacokinetics |
As a chemical linker, this compound does not have a pharmacokinetic profile of its own. The pharmacokinetic properties of the final multivalent conjugates are determined by the overall structure and properties of the molecules, including the ligands attached to the linker.
|
| Toxicity/Toxicokinetics |
This compound is a research-use chemical and is not intended for human therapeutic use. As a linker, it is generally considered to have low inherent toxicity. The potential toxicity of the final multivalent conjugates is determined by the specific ligands and functional groups used.
|
| References |
[1]. Kostiainen MA, et al. Optically degradable dendrons for temporary adhesion of proteins to DNA. Chemistry. 2010 Jun 18;16(23):6912-8.
|
| Additional Infomation |
This compound is a trifunctional branching linker used in dendrimer synthesis and the construction of multivalent molecules. It is a valuable tool for researchers studying multivalency in biological systems and for developing targeted drug delivery systems. The compound is not an approved drug and is not commercially available as a pharmaceutical product.
|
| Molecular Formula |
C25H47NO9
|
|---|---|
| Molecular Weight |
505.64198
|
| Exact Mass |
505.325
|
| CAS # |
175724-30-8
|
| PubChem CID |
11249159
|
| Appearance |
Colorless to light yellow liquid（Density：1.065±0.06 g/cm3）
|
| LogP |
3.629
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
35
|
| Complexity |
569
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NC(COCCC(OC(C)(C)C)=O)(COCCC(OC(C)(C)C)=O)COCCC(OC(C)(C)C)=O
|
| InChi Key |
KPXODPHVWBQJEG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H47NO9/c1-22(2,3)33-19(27)10-13-30-16-25(26,17-31-14-11-20(28)34-23(4,5)6)18-32-15-12-21(29)35-24(7,8)9/h10-18,26H2,1-9H3
|
| Chemical Name |
tert-butyl 3-[2-amino-3-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropoxy]-2-[[3-[(2-methylpropan-2-yl)oxy]-3-oxopropoxy]methyl]propoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9777 mL | 9.8885 mL | 19.7769 mL | |
| 5 mM | 0.3955 mL | 1.9777 mL | 3.9554 mL | |
| 10 mM | 0.1978 mL | 0.9888 mL | 1.9777 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
